Nvidia Partners to Advance 6G Development with AI-Native Network Designs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy NVDA?
Source: Benzinga
- 6G Development Collaboration: Nvidia is collaborating with telecom and technology organizations to advance 6G development, aiming to enhance future wireless systems through open, secure AI-native network designs to meet the demands of increasingly complex machine connectivity.
- AI-RAN Architecture: The company emphasizes that AI-RAN (Artificial Intelligence Radio Access Network) will enable networks to improve continuously through software updates and embedded intelligence, reflecting a necessary shift from traditional network designs to address security and trust challenges.
- Industry Leaders Coalition: Nvidia's founder and CEO Jensen Huang stated that AI is redefining computing and driving the largest infrastructure buildout in human history, with telecommunications being the next beneficiary, highlighting the company's pivotal role in transforming global telecom networks.
- Market Reaction: Despite Nvidia's earnings beating expectations, semiconductor and big tech stocks continued to slide on Monday due to lingering concerns about AI profitability and broader macro pressures, with Nvidia's stock down 1.24% to $175.00 in premarket trading.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVDA
Wall Street analysts forecast NVDA stock price to rise
41 Analyst Rating
39 Buy
1 Hold
1 Sell
Strong Buy
Current: 177.190
Low
200.00
Averages
264.97
High
352.00
Current: 177.190
Low
200.00
Averages
264.97
High
352.00
About NVDA
NVIDIA Corporation is a full-stack computing infrastructure company. The Company is engaged in accelerated computing to help solve the challenging computational problems. The Company’s segments include Compute & Networking and Graphics. The Compute & Networking segment includes its Data Center accelerated computing platforms and artificial intelligence (AI) solutions and software; networking; automotive platforms and autonomous and electric vehicle solutions; Jetson for robotics and other embedded platforms, and DGX Cloud computing services. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating industrial AI and digital twin applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nvidia Shares Decline Once More; New AI Chip May Provide a Boost.
- Earnings Performance: Nvidia was expected to continue its decline following disappointing earnings results.
- New Product Potential: The introduction of a new artificial-intelligence processor may generate renewed interest and excitement for the company.
See More
Nvidia Q4 Earnings Beat but Stock Drops
- Earnings Beat: Nvidia's fourth-quarter earnings exceeded market expectations, although specific figures were not disclosed, analysts believe this reflects the company's strong performance in the artificial intelligence sector, potentially attracting more investor interest.
- Significant Stock Drop: Despite the positive earnings report, Nvidia's stock experienced its largest drop in 10 months during Friday's trading, likely due to market concerns about the overall economic outlook and a reassessment of high valuations by investors.
- Impact of Dollar Weakness: As the US dollar weakens, investors are increasingly looking at the attractiveness of foreign stocks, with analysts suggesting opportunities outside of Nvidia in the AI sector to diversify investment risks and capture potential gains.
- Market Analysis Discussion: Main Street Research's Chief Investment Officer James Demmert discussed with Morning Brief host Julie Hyman how to effectively invest in the current market environment, emphasizing the importance of continued focus on the AI industry and diversified investment strategies.
See More
CoreWeave's Revenue Growth Post-IPO Remains Strong
- Significant Revenue Growth: CoreWeave achieved over 160% year-over-year revenue growth, reaching $5 billion in annual revenue, making it the fastest-growing cloud company in history, highlighting its market potential amid surging AI demand.
- Rapid Customer Expansion: The company reported a nearly 150% increase in customers spending over $1 million, with 80% of these clients also expanding into data storage services, indicating success in diversifying customer needs.
- Capital Expenditure Plans: CoreWeave plans to increase capital spending to at least $30 billion by 2026, double last year's spending, aimed at meeting contracted customer demand, although this poses risks due to its high leverage.
- Robust Contracted Revenue Backlog: CoreWeave currently holds over $66 billion in contracted revenue backlog, indicating a strong demand foundation for the upcoming quarters, despite facing competition and market uncertainties.
See More
Eli Lilly Achieves $1 Trillion Valuation, Remarkable Returns Over a Decade
- Innovation-Driven Growth: Eli Lilly has achieved remarkable returns over the past decade, becoming the largest healthcare stock globally and the first to surpass a $1 trillion valuation, showcasing its leadership in the industry through significant breakthroughs in diabetes and weight management.
- Diversification Strategy: While diabetes drugs are currently the main growth driver, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product portfolio, thereby ensuring long-term business stability and growth potential.
- Technological Investment Outlook: Lilly's partnership with Nvidia aims to create the pharmaceutical industry's most powerful AI supercomputer and establish a research lab, focusing on accelerating the discovery and development of breakthrough therapies, which, although may not yield immediate returns, lays a solid foundation for the future.
- Attractive Dividend Policy: Having more than doubled its dividends in the past five years, Lilly demonstrates strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its core position in a diversified investment portfolio.
See More
CoreWeave's AI Business Continues to Grow
- Significant Revenue Growth: CoreWeave achieved over 160% year-over-year revenue growth, reaching $5 billion in annual revenue, making it one of the fastest-growing cloud companies in history, reflecting strong demand and potential in the AI market.
- Rapid Customer Expansion: The company reported a nearly 150% increase in customers spending over $1 million, with 80% of these clients also expanding into data storage services, indicating success in meeting customer demand.
- Capital Expenditure Plans: CoreWeave plans to increase capital expenditures to at least $30 billion by 2026, double last year's spending, aimed at supporting contracted long-term compute demand, although this raises financial risk for the company.
- Robust Contracted Revenue Backlog: CoreWeave currently has over $66 billion in contracted revenue backlog, indicating strong demand for the upcoming quarters, despite a recent 18% drop in stock price due to market concerns about an AI bubble.
See More
Eli Lilly's Innovations and Dividend Growth Outlook
- Innovation-Driven Growth: Eli Lilly has achieved significant breakthroughs in diabetes and weight management, propelling it to become the largest healthcare stock globally and the first to reach a $1 trillion valuation, showcasing its strong market position and future growth potential.
- Diversification Strategy: While currently relying on the success of tirzepatide, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product lineup, thereby enhancing its long-term competitiveness.
- Technology Investment: Lilly is partnering with Nvidia to build the pharmaceutical industry's most powerful AI supercomputer and research lab, aimed at accelerating the discovery and development of breakthrough therapies; these investments may not yield immediate results but lay a solid foundation for the future.
- Dividend Growth: Over the past five years, Lilly has more than doubled its dividends, reflecting its strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its position as a core holding in investment portfolios.
See More
Nvidia Shares Decline Once More; New AI Chip May Provide a Boost.
- Earnings Performance: Nvidia was expected to continue its decline following disappointing earnings results.
- New Product Potential: The introduction of a new artificial-intelligence processor may generate renewed interest and excitement for the company.
See More
Nvidia Q4 Earnings Beat but Stock Drops
- Earnings Beat: Nvidia's fourth-quarter earnings exceeded market expectations, although specific figures were not disclosed, analysts believe this reflects the company's strong performance in the artificial intelligence sector, potentially attracting more investor interest.
- Significant Stock Drop: Despite the positive earnings report, Nvidia's stock experienced its largest drop in 10 months during Friday's trading, likely due to market concerns about the overall economic outlook and a reassessment of high valuations by investors.
- Impact of Dollar Weakness: As the US dollar weakens, investors are increasingly looking at the attractiveness of foreign stocks, with analysts suggesting opportunities outside of Nvidia in the AI sector to diversify investment risks and capture potential gains.
- Market Analysis Discussion: Main Street Research's Chief Investment Officer James Demmert discussed with Morning Brief host Julie Hyman how to effectively invest in the current market environment, emphasizing the importance of continued focus on the AI industry and diversified investment strategies.
See More
CoreWeave's Revenue Growth Post-IPO Remains Strong
- Significant Revenue Growth: CoreWeave achieved over 160% year-over-year revenue growth, reaching $5 billion in annual revenue, making it the fastest-growing cloud company in history, highlighting its market potential amid surging AI demand.
- Rapid Customer Expansion: The company reported a nearly 150% increase in customers spending over $1 million, with 80% of these clients also expanding into data storage services, indicating success in diversifying customer needs.
- Capital Expenditure Plans: CoreWeave plans to increase capital spending to at least $30 billion by 2026, double last year's spending, aimed at meeting contracted customer demand, although this poses risks due to its high leverage.
- Robust Contracted Revenue Backlog: CoreWeave currently holds over $66 billion in contracted revenue backlog, indicating a strong demand foundation for the upcoming quarters, despite facing competition and market uncertainties.
See More
Eli Lilly Achieves $1 Trillion Valuation, Remarkable Returns Over a Decade
- Innovation-Driven Growth: Eli Lilly has achieved remarkable returns over the past decade, becoming the largest healthcare stock globally and the first to surpass a $1 trillion valuation, showcasing its leadership in the industry through significant breakthroughs in diabetes and weight management.
- Diversification Strategy: While diabetes drugs are currently the main growth driver, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product portfolio, thereby ensuring long-term business stability and growth potential.
- Technological Investment Outlook: Lilly's partnership with Nvidia aims to create the pharmaceutical industry's most powerful AI supercomputer and establish a research lab, focusing on accelerating the discovery and development of breakthrough therapies, which, although may not yield immediate returns, lays a solid foundation for the future.
- Attractive Dividend Policy: Having more than doubled its dividends in the past five years, Lilly demonstrates strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its core position in a diversified investment portfolio.
See More
CoreWeave's AI Business Continues to Grow
- Significant Revenue Growth: CoreWeave achieved over 160% year-over-year revenue growth, reaching $5 billion in annual revenue, making it one of the fastest-growing cloud companies in history, reflecting strong demand and potential in the AI market.
- Rapid Customer Expansion: The company reported a nearly 150% increase in customers spending over $1 million, with 80% of these clients also expanding into data storage services, indicating success in meeting customer demand.
- Capital Expenditure Plans: CoreWeave plans to increase capital expenditures to at least $30 billion by 2026, double last year's spending, aimed at supporting contracted long-term compute demand, although this raises financial risk for the company.
- Robust Contracted Revenue Backlog: CoreWeave currently has over $66 billion in contracted revenue backlog, indicating strong demand for the upcoming quarters, despite a recent 18% drop in stock price due to market concerns about an AI bubble.
See More
Eli Lilly's Innovations and Dividend Growth Outlook
- Innovation-Driven Growth: Eli Lilly has achieved significant breakthroughs in diabetes and weight management, propelling it to become the largest healthcare stock globally and the first to reach a $1 trillion valuation, showcasing its strong market position and future growth potential.
- Diversification Strategy: While currently relying on the success of tirzepatide, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product lineup, thereby enhancing its long-term competitiveness.
- Technology Investment: Lilly is partnering with Nvidia to build the pharmaceutical industry's most powerful AI supercomputer and research lab, aimed at accelerating the discovery and development of breakthrough therapies; these investments may not yield immediate results but lay a solid foundation for the future.
- Dividend Growth: Over the past five years, Lilly has more than doubled its dividends, reflecting its strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its position as a core holding in investment portfolios.
See More
